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Abstract
Background: The efficacy of a combination of a calcium channel blocker (CCB) plus chlorthalidone (diuretic) versus
a CCB plus an angiotensin receptor blocker (ARB) in patients not responding to CCB monotherapy has not been
evaluated previously. We plan to compare the efficacy and safety of S-amlodipine (CCB) plus chlorthalidone versus
S-amlodipine plus telmisartan (ARB) combinations among hypertension patients unresponsive to amlodipine monotherapy.
Methods/design: This study is a prospective, randomized, double-blind, multicenter, parallel, non-inferiority phase 4 study.
Hypertension patients who have been treated with amlodipine (5 mg) or S-amlodipine (2.5 mg) monotherapy for
≥2 weeks and whose mean diastolic blood pressure (DBP) is greater than 90 mmHg will be randomized to either
S-amlodipine (2.5 mg) plus chlorthalidone (25 mg) or S-amlodipine (2.5 mg) plus telmisartan (40 mg) therapy. The
primary efficacy endpoint is mean sitting DBP change after 12 weeks of treatment. The study objective is to prove the
non-inferiority of the former combination (test drug) as compared to the latter one (control) with a non-inferiority
margin of 3 mmHg in mean DBP change. The secondary endpoints are 6-week DBP change, 6- and 12-week sitting
systolic BP (SBP) change, and the attainment of the target BP (SBP < 140 mmHg or DBP < 90 mmHg). Urine albumin,
albumin/creatinine ratio (ACR), pulse wave velocity, central BP, 24-h ambulatory BP monitoring, and body fluid composition
analysis will be performed at each hospital’s discretion. The sample size was estimated as 170 in total with 1:1 randomization.
Discussion: This is the first study comparing the efficacy of a CCB plus chlorthalidone versus a CCB plus an ARB in patients
who are not responding to CCB single therapy. The study result will help clinicians to choose between chlorthalidone and
telmisartan in CCB-unresponsive patients.
Trial registration: ClinicalTrials.gov, NCT03226340. Registered on 2 December 2015.
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Background
Hypertension is the most prevalent disease worldwide
and a leading cause of cardiovascular mortality and mor-
bidity [1]. Its treatment has proven prolonging survival
and reducing ischemic heart disease and stroke [2].
Most patients with hypertension need to be treated
with antihypertensive medication, and some require two
or more antihypertensive drugs [3]. A Korean study re-
ported that 46% of hypertension patients are treated
with two or more drugs, 38% with two drugs, and 8%
with three or more drugs [4]. Accordingly, it is import-
ant to determine the most appropriate combination of
antihypertensive agents. However, clinical trials compar-
ing each combination therapy are scarce.
In the representative large-scale “Avoiding Cardiovas-
cular Events in Combination Therapy in Patients Living
with Systolic Hypertension (ACCOMPLISH)” study, the
efficacy of an angiotensin-converting enzyme inhibitor
(ACEI) plus a calcium channel blocker (CCB) was com-
pared with that of an ACEI plus a diuretic, and the study
demonstrated the superiority of the former combination
based on clinical outcomes, despite a similar blood pres-
sure (BP) reduction in both groups [5].
Among possible two-drug combination regimens, the
European Society of Cardiology (ESC) guideline on ar-
terial hypertension recommends CCBs and diuretics as
the central drugs for the combination [6]. The guideline
suggests addition of ACEIs, angiotensin receptor
blockers (ARBs), and diuretics to CCB monotherapy,
and as add-on drugs to diuretics, ARBs, ACEIs, and
CCBs are recommended. Considering the similarity be-
tween ACEIs and ARBs, we can assume the major three-
combination regimens as ACEI/ARB + CCB, ACEI/ARB
+ diuretic, and CCB + diuretic.
Combination regimen comparisons other than that
mentioned in the ACCOMPLISH study (ACEI/ARB +
CCB versus ACEI/ARB + diuretic) are ([ACEI/ARB +
CCB] versus [CCB + diuretic]) and ([ACEI/ARB + diur-
etic] versus [CCB + diuretic]). Our study deals with the
former one.
Each drug of the CCB + diuretic combination (amlodi-
pine/S-amlodipine and thiazide/chlorthalidone) has been
extensively studied [7, 8], and the American and
European guidelines on hypertension treatment recom-
mend the combination of CCB + diuretic [9, 10]. This
combination has demonstrated good efficacy and safety
in some studies [11–13]. However, it is not as commonly
used as the renin–angiotensin–aldosterone antagonist-
based combination. The CCB + diuretic combination has
only been compared with combinations, such as beta-
blocker + diuretic [14] and ARB + diuretic [15], in large-
scale clinical trials. A randomized clinical trial investi-
gated the difference between CCB + diuretic and CCB +
ARB combinations by comparing three regimens:
benidipine + thiazide diuretic, benidipine + ARB, and
benidipine + beta-blocker, and cardiovascular outcomes
and BP-lowering effects with benidipine + thiazide and
benidipine + ARB were similar [16]. In contrast to hy-
drochlorothiazide used in this reported trial, we have
chosen chlorthalidone as the diuretic as it is associated
with better clinical outcomes and BP-lowering efficacy
and lower adverse effects than hydrochlorothiazide;
however, this report is controversial [17, 18]. In fact,
chlorthalidone is rarely used in Korea and hydrochloro-
thiazide is the most commonly used diuretic. Accord-
ingly, there is a lack of data regarding single and
combination therapies with chlorthalidone in Korea.
In this clinical trial, we plan to compare the efficacy
and safety between S-amlodipine plus chlorthalidone
(diuretic) combination as the test combination regimen
and S-amlodipine plus telmisartan (ARB) as control in
patients with hypertension who do not adequately re-
spond to CCB monotherapy.
Methods/design
Overall design
This study is a prospective, randomized, double-blind,
multicenter, parallel, non-inferiority phase 4 study to
compare the efficacy and safety between S-amlodipine
plus chlorthalidone (diuretic) and S-amlodipine plus tel-
misartan combination therapies in patients with hyper-
tension who do not adequately respond to CCB
monotherapy.
Ten tertiary university hospitals in Korea are to par-
ticipate in this study. Patients with essential hyperten-
sion who have a medical history of treatment with
amlodipine (5 mg) or S-amlodipine (2.5 mg) monother-
apy for ≥2 weeks prior to screening and whose mean
sitting diastolic BP (DBP) is >90 mmHg are considered
as potential subjects for this study. Those who have
completed the final compatibility evaluation will be
randomly assigned to either the test group (S-amlodi-
pine 2.5 mg + chlorthalidone 25 mg) or the control
group (S-amlodipine 2.5 mg + telmisartan 40 mg) in a
1:1 ratio. The study subjects in both groups will receive
an oral dose of the test or control drugs plus a match-
ing placebo once daily for a total of 12 weeks and will
be evaluated for safety and efficacy. They will visit the
outpatient clinic three times, including screening dur-
ing the study period (Fig. 1).
The trial is approved by the relevant institutional re-
view board of each center and is registered at Clinical
Trials.gov (identifier no. NCT03226340).
For a detailed overview, see the Standard Protocol
Items: Recommendations for Interventional Trials
(SPIRIT) figure (Fig. 2). The SPIRIT checklist is provided
as Additional file 1.
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Fig. 1 Overall scheme of the study
Fig. 2 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT)
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Study objective
The study aim is to demonstrate the non-inferiority
(non-inferiority margin of 3 mmHg in DBP) of the
S-amlodipine plus chlorthalidone combination therapy
compared to the S-amlodipine plus telmisartan combin-




1. Male and female patients with essential hypertension,
aged between 18 and 80 years.
2. Patients who are confirmed to be treated with
amlodipine or S-amlodipine monotherapy for
≥2 weeks immediately prior to screening.
3. Patients whose mean sitting DBP is >90 mmHg,
which is confirmed by triplicate measurements
from the reference arm at screening.
4. Patients who have signed the informed consent by
the study associate.
Exclusion criteria
1. Patients with a history of secondary hypertension and
suspected secondary hypertension including
coarctation of the aorta, primary hyperaldosteronism,
renal artery stenosis, Cushing’s syndrome,
pheochromocytoma, and polycystic kidney disease.
2. Patients with a mean systolic BP (SBP) ≥ 200 mmHg
or DBP ≥ 110 mmHg at the screening visit.
3. Patients with ≥20 mmHg difference between the
highest and the lowest sitting SBP or ≥10 mmHg
difference between the highest and the lowest DBP,
which is confirmed by triplicate measurements
from the reference arm at screening.
4. Patients with uncontrolled diabetes (HbA1c ≥ 9.0%).
5. Patients who have been continuously taking other
medicines, such as systemic steroids, thyroid
hormones, oral contraceptives (except for menopausal
hormone replacement therapy), psychiatric drugs,
NSAIDs, sympathetic drugs, and immune
suppressants, which have the potential to affect the BP.
6. Patients with symptomatic orthostatic hypotension.
7. Patients with a history of malignant tumors,
including leukemia and lymphoma, within the
past 5 years.
8. Patients with a history of autoimmune diseases,
such as rheumatoid arthritis and systemic lupus
erythematosus.
9. Patients with a history of hypersensitivity to
S-amlodipine nicotinate or other drugs containing
chlorthalidone or telmisartan.
10. Patients with clinically significant kidney and liver
diseases, such as those on dialysis, liver cirrhosis,
biliary obstruction, and hepatic failure, or those
who show the following findings at screening visit:
– Alanine transaminase or aspartate transaminase
level is at least three times higher than the
normal upper limit.
– Total bilirubin level is more than twice the
normal upper limit.
– Blood urea nitrogen level is more than twice the
normal upper limit.
– Alkaline phosphatase level is more than twice
the normal upper limit.
– Creatinine clearance level is less than 10 mL/min.
11. Patients with a history of the following diseases in
the past 6 months, which are determined to be
clinically significant by the investigator:
– Heart failure (NYHA classes III and IV), ischemic
heart diseases (coronary artery diseases, such as
angina pectoris and myocardial infarction),
peripheral vascular diseases, hemodynamically
significant valve stenosis, and arrhythmia.
– Severe cerebrovascular events, including stroke,
cerebral infarction, and cerebral hemorrhage.
12. Patients with shock.
13. Patients with a history of alcohol or drug abuse.
14. Patients with potential pregnancy or who are
breastfeeding.
15. Patients who are judged by the investigator to be
inadequate to participate in the clinical study both
legally and psychologically.
16. Patients who have participated in clinical studies
with other investigational drug products within
4 weeks prior to screening.
Study drugs
The test drugs are a combination of Lodien tablet, 2.
5 mg (S-amlodipine 2.5 mg, Hanlim Pharmaceutical Co.,
Ltd.) plus Hygroton tablet, 25 mg (chlorthalidone
25 mg, Hanlim Pharmaceutical Co., Ltd.). The control
drugs are a combination of Lodien tablet, 2.5 mg plus
Micardis tablet, 40 mg (telmisartan 40 mg, Boehringer
Ingelheim Korea Co., Ltd.). The patients are recom-
mended to take both the tablets (test or control drugs)
and matching placebo (totally three tablets) at the same
time once a day for 12 weeks (Fig. 1).
Endpoints
The primary endpoint is to demonstrate the non-
inferiority of the S-amlodipine plus chlorthalidone
combination therapy compared to the S-amlodipine plus
telmisartan combination therapy based on the difference
in sitting DBP after 12 weeks of treatment. The second-
ary endpoints are mean sitting DBP change at 6 weeks,
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6- and 12-week sitting SBP change, and the attainment
of the target BP (SBP < 140 mmHg or DBP < 90 mmHg)
at 12 weeks.
Investigational endpoint
The following tests are to be carried out at the discretion
of each investigator according to the availability of the
medical devices for the measurement at the screening
point and visit 3.
1. Pulse wave velocity
Measurement of the left and right brachial–ankle pulse
wave velocity.
2. Central blood pressure
Waveforms directly to be measured from the carotid ar-
tery or by applying pressure to the radial artery using a
sensor will be obtained using a general transfer formula.
3. 24-h ambulatory BP monitoring
The BP cuff will be wrapped around the upper arm
and connected to a portable monitor for monitoring the
BP for 24 h. The BP will be measured every 15 min dur-
ing the day and every 30 min during the night, and the
measurement interval can be defined differently.
4. Body fluid composition analysis using InBody720
(body water, edema index)
It will be automatically calculated and confirmed by
the measuring equipment.
Sample size estimation
We have referred to two studies for sample size estima-
tion. One study is regarding a combination therapy with
chlorthalidone or valsartan as an add-on drug to diltia-
zem [19], and the other one compared amlodipine with
hydrochlorothiazide versus telmisartan [20]. We have
also referred to the Korea Ministry of Food and Drug
Safety review data on amlodipine/telmisartan combin-
ation [21]. With these references, we calculated the
number of patients by assuming the mean change in
DBP will be equal in the intervention and control arms
and the standard deviation of mean DBP change as 7.
2 mmHg in the test group. The alpha error is estimated
as 0.05 (one-tailored) and beta error as 0.2. The non-
inferiority margin for DBP change in the clinical setting
of hypertension is stated as 3 in the Guideline on As-
sessment by the Ministry of Food and Drug Safety [21];
therefore, we estimated the sample size as 72 and the
final size as 85 in each group considering 15% patients
will be lost to follow-up.
Statistical analysis
To identify inter-group difference in the demographic
variables and the baseline information at the time point
prior to the study initiation, continuous data will be
compared by the two-sample t test or Wilcoxon’s rank
sum test and categorical data by the chi-square test or
Fisher’s exact test.
To verify that the mean DBP variation in the S-
amlodipine 2.5 mg plus chlorthalidone 25 mg (test)
group is non-inferior to that in the S-amlodipine 2.5 mg
plus telmisartan 40 mg (control) group, the mean DBP
change at week 12 post treatment from the baseline in
the two groups will be obtained. If the lower limit of
95% confidence interval is larger than −3 mmHg using
the one-tailed t test with a significance level of 0.05, the
test drug combination would be considered non-inferior
to the control drug combination.
Firstly, we will test the normality using the normal
probability plot, a quantile–quantile plot (QQ plot), and
perform the Kolmogorov–Smirnov test and Shapiro–
Wilk test. If normality is not guaranteed, non-parametric
tests such as the Mann–Whitney U test or Wilcoxon
rank sum test will be applied.
Regarding adjustment for covariates, because this is a
randomized controlled trial, we believe that the patient
characteristics will be well balanced between the groups.
However, should there be significant differences between
groups, we will adjust for those variables during statis-
tical analysis. ANCOVA will be conducted with the
baseline DBP level as a covariate. If the lower limit of
the 95% confidence interval for the difference by sub-
tracting the change in the test group from that in the
control group is greater than −3 mmHg after ANCOVA,
the mean DBP decrease in the test group can be proven
to be non-inferior to that in the control group.
Randomization
Randomization will be performed according to a prede-
signed block randomization method. The randomization
block will be generated by an independent statistician
who is unrelated to this study using the SAS
randomization program. Randomization will be per-
formed in a 1:1 ratio in a consecutive order.
Analysis
Intention-to-treat analysis set (full analysis set)
Data from all subjects in both groups who are randomly
assigned to the primary analysis of efficacy assessment
will be subjected to intention-to-treat analysis assuming
that the patients have taken the investigational products
at least once, and the efficacy assessment will be
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performed at least once after the time point of baseline
evaluation and after the administration of the investiga-
tional products.
Per-protocol analysis set
In the per-protocol analysis set (PPS) that is subjected to
the secondary analysis of efficacy assessment, any of the
following subjects who are considered to present major
deviations from the clinical study protocol will be ex-
cluded from the analysis.
1. Subjects who have not completed the period specified
in the study protocol and have withdrawn early.
2. Study subjects whose medication compliance with
the investigational products is less than 75%.
3. Study subjects who are determined to present
major deviations from the study protocol.
4. Subjects who violate the inclusion/exclusion criteria.
Safety set
The subjects who are randomly assigned and have taken
the investigational products at least once and whose
safety-related data are confirmed via telephone or hos-
pital visit by the investigator will be included in the
safety set. Efficacy analysis will be conducted on the full
analysis set (FAS) and the PPS. Demographic data will
be obtained from the FAS, while safety assessment will
be performed on the safety set.
In case of missing data at a certain time point or if the
subject drops out before the close-out of the clinical
study, the last observation carried forward (LOCF)
method will be applied to verify the efficacy. The ana-
lysis is limited to patients for whom the efficacy assess-
ment has been conducted once from the baseline. The
safety analysis will be conducted with the raw data with-
out applying the LOCF method.
Discussion
Multiple drug therapy ought to be considered by physi-
cians to manage the BP adequately in hypertension pa-
tients. Although a number of studies have reported that
two drugs or more are needed to control the BP [3, 5,
22], studies on the head-to-head comparison of two-
drug combination regimens are scarce. This study
compares two regimens of combination therapy in a
head-to-head manner to demonstrate the non-inferiority
of CCB + diuretic in BP-lowering efficacy and safety
compared to CCB + ARB as a combination therapy.
CCBs are one of the most widely used antihypertensive
drugs in the world, including Korea, mainly due to their
reliable BP-lowering efficacy and low adverse event rate
as well as good clinical outcomes [22]. The selection of
another medication in addition to CCBs is of importance
when the BP is not controlled with CCB monotherapy.
ACEIs, ARBs, and diuretics may be combined with
CCBs. However, studies comparing the efficacy and
safety of these add-on drugs in patients with an uncon-
trolled BP are lacking. We compare chlorthalidone
(diuretic) as the active drug versus telmisartan (ARB) as
the comparator after combining with S-amlodipine
(CCB). The reason for adding chlorthalidone as the diur-
etic is its better clinical and preclinical BP-lowering ef-
fect, fewer adverse effects, and better clinical outcomes
than hydrochlorothiazide. Although little evidence exists
on the superiority of chlorthalidone over telmisartan as
an add-on to CCB monotherapy, we can assume that
chlorthalidone might be more effective in volume-
dependent and salt-sensitive hypertension patients than
telmisartan; moreover, chlorthalidone is less expensive.
Importantly, the lack of evidence regarding the compari-
son justifies the purpose of this clinical trial.
S-amlodipine, produced by Hanlim Pharmaceutical
Co., Ltd., in Korea, is a chiral drug, which was developed
because the biological activities of R-amlodipine and
S-amlodipine are not the same. Amlodipine is a racemic
mixture of S-amlodipine and R-amlodipine in a ratio of
1:1, and S-amlodipine, which acts as a CCB, could be
separated by optical methods. S-amlodipine reduces the
dose and adverse effects of the racemic mixture of amlo-
dipine. Therefore, the combination of S-amlodipine and
chlorthalidone is a good option for controlling the BP in
patients unresponsive to CCB monotherapy. Amlodipine
plus telmisartan is a good comparator regimen owing to
its similarity with the amlodipine plus benazepril com-
bination, the efficacy and safety of which have been re-
ported in the ACCOMPLISH study [5]. Additionally, the
BP-lowering effects of both drugs of the combination
have been clinically validated [23–25]. Although we
propose to investigate the change in BP within a short
period, instead of long-term clinical outcomes, we are
certain that the results of our study will clarify existing
knowledge on the efficacy and safety of CCB + diuretic
and will provide clinicians with another option for treat-
ing hypertension in patients who do not respond ad-
equately to treatment with a single agent.
Other ancillary parameters, such as pulse wave velocity,
central blood pressure, 24-h ambulatory BP monitoring,
and body fluid composition analysis, in some patients will
give additional insight into the change in aortic stiffness,
BP control throughout the day, and effect on edema,
which is the major adverse effect of CCBs. If a meaningful
difference is observed between the two combinations, it
will also allow physicians to better choose drugs in com-
bination, especially for patients experiencing adverse
effects of the currently used therapy and in special clinical
situations, such as heart failure.
Whether the study results are positive or not, this
study is valuable because it is the first comparison
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between S-amlodipine + chlorthalidone and S-
amlodipine + telmisartan and will facilitate the selection
of the most appropriate combination regimen for treat-
ing patients not responding to single antihypertensive
therapy. This study comparing S-amlodipine + chlortha-
lidone versus S-amlodipine + telmisartan in hyperten-
sion patients whose BP is not controlled with
amlodipine monotherapy will help clinicians to select
the add-on drug for better controlling the BP in hyper-
tension patients.
Trial status
The trial (ClinicalTrials.gov, identifier number:
NCT03226340) is currently ongoing and is in the re-
cruitment phase. Recruitment began on 2 December
2015 and is expected to finish in 2018.
Additional file
Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 124 kb)
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